Epidermal growth factor receptor targeting and challenges in glioblastoma
Open Access
- 10 January 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (7), 914-918
- https://doi.org/10.1093/neuonc/nov319
Abstract
With the evolution of technology, there is now a deeper understanding of glioblastoma as an inter- and intraheterogeneous disease comprising a multitude of genetically and epigenetically different cancer cells. Greater characterization of glioblastoma at the molecular level has improved its initial pathophysiological staging and classification. With this knowledge comes the hope that more efficacious therapies to combat this highly lethal disease are on the horizon. One possibility for intervention is represented by the targeting of epidermal growth factor receptor (EGFR), which is amplified and mutated in a large subset of patients. In this review, we provide a brief overview of EGFR and its mutated form, EGFR variant III, describing the downstream cellular pathways activated by each receptor, available animal models, therapeutic strategies to inhibit the receptor, and possible intervention routes to efficiently target this receptor and prevent the emergence of resistant mechanisms which to date have hampered a successful therapeutic outcome.Keywords
This publication has 31 references indexed in Scilit:
- Emerging insights into the molecular and cellular basis of glioblastomaGenes & Development, 2012
- Genetic modeling of gliomas in mice: New tools to tackle old problemsGlia, 2011
- Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitationsChinese Journal of Cancer, 2011
- Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastomaGenes & Development, 2010
- Oncogenic EGFR Signaling Networks in GliomaScience Signaling, 2009
- A Drosophila Model for EGFR-Ras and PI3K-Dependent Human GliomaPLoS Genetics, 2009
- Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted TherapiesScience, 2007
- Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastomaProceedings of the National Academy of Sciences, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005